Sugar and sugar-free liquid formulations of delamanid for patients with rifampicin-resistant TB

BACKGROUND: Delamanid (DLM) tablets are recommended for the treatment of rifampicin-resistant TB. However, no liquid or dispersible tablet formulation of DLM is currently commercially available for patients with challenges ingesting these tablets. The aim of this study was to develop stable extempor...

Descripción completa

Detalles Bibliográficos
Autores principales: Taneja, R., Nahata, M. C., Scarim, J., Pande, P. G., Scarim, A., Hoddinott, G., Fourie, C. L., Jew, R. K., Schaaf, H. S., Garcia-Prats, A. J., Hesseling, A. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Union Against Tuberculosis and Lung Disease 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879082/
https://www.ncbi.nlm.nih.gov/pubmed/36853133
http://dx.doi.org/10.5588/ijtld.22.0329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879082/
https://www.ncbi.nlm.nih.gov/pubmed/36853133
http://dx.doi.org/10.5588/ijtld.22.0329

Ejemplares similares